XHKG
1875
Market cap330mUSD
Oct 09, Last price
3.56HKD
1D
-0.56%
1Q
-0.84%
IPO
-42.39%
Name
TOT BIOPHARM International Co Ltd
Chart & performance
P/E
—
P/S
2.94
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.92%
Rev. gr., 5y
101.53%
Revenues
748m
-31.93%
Net income
-100m
L
CFO
16m
-86.13%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.
Key people
Shan Fu
Non-Executive Chairman of the Board · since 2018
Jun Liu
Chief Executive Officer, Chief Scientific Officer, Executive Director · since 2020
Chun- Ying Yeh- Huang
Non-Executive Vice Chairman of the Board · since 2023
Qing Duan
Senior Director of the New Drug Development · since 2019
Shan Feng
Senior Director of the Regulatory Affairs Department · since 2019
Chih- Yuan Wu
Senior Director of the Strategy and Business Development · since 2019
Ben Xiao
Senior Finance Director · since 2022
Yifan Chen
Joint Company Secretary, Senior Director of the Legal Division · since 2022
Wing Yat Lui
Joint Company Secretary
Weidong Liu
Non-Executive Director · since 2023
Xuelin Gu
Independent Non-Executive Director · since 2025
Hui Sun
Independent Non-Executive Director · since 2025
Qing Zhang
Independent Non-Executive Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||